MK 8353

Drug Profile

MK 8353

Alternative Names: MK-8353; SCH-900353

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck Sharp & Dohme
  • Class Antineoplastics
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 21 Nov 2016 Investigation in Colorectal cancer in USA (PO) before November 2016
  • 21 Nov 2016 Merck Sharp & Dohme plans a phase Ib trial for Solid tumours and Colorectal cancer (Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02972034)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(First-line therapy, Late-stage disease) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top